The results show that targeting apoE in both the tumor cells and the host (apoE-/- B16 cells injected into apoE-/- C57/BL6 mice) results in delayed tumor growth (Figure 5), and significant rejection of tumor cell inoculation with improved overall survival (Figure 6). The gene discussed is APOE; the disease is neoplasm.